Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eDREAM study of GAL-101 ophthalmic solution for non-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration
2024-519128-26-00Phase 2Authorised
- Sponsor
- Galimedix Therapeutics
- Start
- May 2025
- Modality
- Small Molecules, Peptides
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in geographic atrophy (GA) and age-related macular degeneration (AMD) comparing GAL-101 ophthalmic solution with Matching placebo ophthalmic solution (2 arms). Primary endpoint: Annual rate of change in geographic atrophy area. Planned start May 2025; status: authorised.
02
Drugs
gal-101
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2024-519128-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519128-26-00.